Relay Therapeutics, Inc.
RLAYNASDAQHealthcare● Active
$13.82
+$0.30(+2.22%)
Market Cap$2.4B
P/E Ratio—
52W High$17.47
52W Low$2.98
Relay Therapeutics, Inc. (RLAY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RLAY · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.41
Est. -$0.36 · -12.9%
Revenue
$0.00B
Est. $0.01B · -46.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
RLAY reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.42 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.36 | -$0.41 | -12.9% | $0.00B | $0.01B | -46.2% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.38 | -$0.32 | +15.8% | $0.01B | $0.00B | +41.0% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.39 | -$0.43 | -10.3% | — | $0.00B | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.49 | -$0.41 | +16.3% | $0.00B | $0.00B | +4637.6% |
| ▲ Q2 FY2025 | May 5, 2025 | -$0.50 | -$0.46 | +8.0% | $0.01B | $0.00B | +104.1% |
| ▲ Q1 FY2025 | Feb 26, 2025 | -$0.57 | -$0.45 | +21.1% | — | $0.01B | — |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.77 | -$0.63 | +18.2% | — | $0.00B | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.42
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$0.41
EPS Est.
-$0.36
EPS Surpr.
-12.9%
Revenue
$0.00B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.32
EPS Est.
-$0.38
EPS Surpr.
+15.8%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.43
EPS Est.
-$0.39
EPS Surpr.
-10.3%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.41
EPS Est.
-$0.49
EPS Surpr.
+16.3%
Revenue
$0.00B
Q2 FY2025
May 5, 2025Beat
EPS Actual
-$0.46
EPS Est.
-$0.50
EPS Surpr.
+8.0%
Revenue
$0.01B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$0.45
EPS Est.
-$0.57
EPS Surpr.
+21.1%
Revenue
—
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.63
EPS Est.
-$0.77
EPS Surpr.
+18.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.53 | $-0.29 | $-0.02 | 5 |
| Q3 FY2028 | $-0.71 | $-0.39 | $-0.02 | 5 |
| Q2 FY2028 | $-0.71 | $-0.39 | $-0.02 | 6 |
| Q1 FY2028 | $-0.70 | $-0.38 | $-0.02 | 3 |
| Q4 FY2027 | $-0.71 | $-0.39 | $-0.02 | 2 |
| Q3 FY2027 | $-0.73 | $-0.40 | $-0.02 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -12.9% | $13.09 | $13.00 | -0.69% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +15.8% | $9.22 | $9.16 | -0.65% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -10.3% | $6.55 | $6.53 | -0.31% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +16.3% | $3.53 | $3.49 | -1.13% |
| ▲ Q2 FY2025 | May 5, 2025 | +8.0% | $3.25 | $3.32 | +2.15% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +21.1% | $3.68 | $3.75 | +1.90% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +18.2% | $5.95 | $6.25 | +5.04% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +5.5% | $7.10 | $7.19 | +1.27% |
Q2 FY2026-0.69%
Report Date
May 5, 2026
EPS Beat/Miss
-12.9%
Price Before
$13.09
Price After
$13.00
Q1 FY2026-0.65%
Report Date
Feb 26, 2026
EPS Beat/Miss
+15.8%
Price Before
$9.22
Price After
$9.16
Q4 FY2025-0.31%
Report Date
Nov 6, 2025
EPS Beat/Miss
-10.3%
Price Before
$6.55
Price After
$6.53
Q3 FY2025-1.13%
Report Date
Aug 7, 2025
EPS Beat/Miss
+16.3%
Price Before
$3.53
Price After
$3.49
Q2 FY2025+2.15%
Report Date
May 5, 2025
EPS Beat/Miss
+8.0%
Price Before
$3.25
Price After
$3.32
Q1 FY2025+1.90%
Report Date
Feb 26, 2025
EPS Beat/Miss
+21.1%
Price Before
$3.68
Price After
$3.75
Q4 FY2024+5.04%
Report Date
Nov 6, 2024
EPS Beat/Miss
+18.2%
Price Before
$5.95
Price After
$6.25
Q3 FY2024+1.27%
Report Date
Aug 6, 2024
EPS Beat/Miss
+5.5%
Price Before
$7.10
Price After
$7.19
Avg Beat Reaction+1.43%
Avg Miss Reaction-0.50%
Beat Rate6 / 8 quarters
Largest Move+5.04% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RLAY ends December
Relay Therapeutics, Inc. (RLAY) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.41 — missing the analyst consensus of $-0.36 by -12.9%. The next RLAY earnings date is expected around September 1, 2026.
Each quarter, investors track RLAY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RLAY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RLAY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RLAY earnings · 5 questionsRelay Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. RLAY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RLAY historically reports after market close (AMC).
RLAY earnings datewhen is RLAY earningsRLAY next earnings datewhen does RLAY report earningsRLAY earnings calendar
▸ Source: FMP · Relay Therapeutics, Inc. SEC filings · US GAAP · Relay Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026